Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -99.00% | -.--% | -.--% |
Valuation
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Capitalization 1 | 0.00007 | 0.008539 | 0.000853 | 0.008429 | 0.008187 | 0.008873 |
Enterprise Value (EV) 1 | 0.3211 | 0.123 | 0.1743 | 0.284 | 0.3432 | 0.4239 |
P/E ratio | -0 x | -0.07 x | -0.01 x | -0.12 x | -0.15 x | -0.12 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | -1.28 x | -1.31 x | -2.51 x | -5.67 x | -8.66 x | -7.24 x |
EV / FCF | -5.3 x | -0.54 x | -10.7 x | -4.33 x | -12.2 x | -10.4 x |
FCF Yield | -18.9% | -187% | -9.36% | -23.1% | -8.22% | -9.65% |
Price to Book | -0 x | -0.06 x | -0 x | -0.03 x | -0.02 x | -0.02 x |
Nbr of stocks (in thousands) | 54,431 | 64,431 | 64,431 | 64,431 | 64,431 | 64,431 |
Reference price 2 | 0.000001 | 0.000133 | 0.000013 | 0.000131 | 0.000127 | 0.000138 |
Announcement Date | 30/04/18 | 29/04/19 | 29/04/20 | 29/04/21 | 29/04/22 | 26/04/23 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net sales | - | - | - | - | - | - |
EBITDA 1 | -0.2506 | -0.0938 | -0.0694 | -0.0501 | -0.0396 | -0.0585 |
EBIT 1 | -0.2515 | -0.0951 | -0.0703 | -0.0507 | -0.04 | -0.0588 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -0.2675 | -0.123 | -0.0866 | -0.0686 | -0.0562 | -0.0759 |
Net income 1 | -0.2675 | -0.123 | -0.0866 | -0.0686 | -0.0562 | -0.0759 |
Net margin | - | - | - | - | - | - |
EPS 2 | -0.004915 | -0.001918 | -0.001344 | -0.001065 | -0.000871 | -0.001178 |
Free Cash Flow 1 | -0.0606 | -0.2297 | -0.0163 | -0.0656 | -0.0282 | -0.0409 |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 30/04/18 | 29/04/19 | 29/04/20 | 29/04/21 | 29/04/22 | 26/04/23 |
Balance Sheet Analysis
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net Debt 1 | 0.32 | 0.11 | 0.17 | 0.28 | 0.33 | 0.42 |
Net Cash position 1 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | -1.281 x | -1.22 x | -2.498 x | -5.503 x | -8.457 x | -7.09 x |
Free Cash Flow 1 | -0.06 | -0.23 | -0.02 | -0.07 | -0.03 | -0.04 |
ROE (net income / shareholders' equity) | 69.7% | 37.4% | 47.2% | 26.3% | 17.4% | 19.5% |
ROA (Net income/ Total Assets) | -49.6% | -18.8% | -883% | -756% | -690% | -1,101% |
Assets 1 | 0.5391 | 0.6547 | 0.009808 | 0.009072 | 0.008141 | 0.006894 |
Book Value Per Share 2 | -0.0100 | -0 | -0 | -0 | -0.0100 | -0.0100 |
Cash Flow per Share 2 | 0 | 0 | 0 | 0 | 0 | 0 |
Capex 1 | 0 | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 30/04/18 | 29/04/19 | 29/04/20 | 29/04/21 | 29/04/22 | 26/04/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-.--% | 64 | |
+33.18% | 709B | |
+30.78% | 595B | |
-2.36% | 367B | |
+20.28% | 334B | |
+4.98% | 289B | |
+14.17% | 239B | |
+9.20% | 211B | |
-3.35% | 203B | |
+8.71% | 171B |
- Stock Market
- Equities
- FPSUF Stock
- Financials Capha Pharmaceuticals Inc.